Imlunestrant (LY-3484356)

Imlunestrant (LY-3484356) is an orally active, nonsteroidal selective estrogen receptor degrader (SERD) and estrogen receptor antagonist developed for the treatment of hormone receptor-positive breast cancer.

Chemical Name: (R)-5-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol

Molecular Formula: C₂₉H₂₄F₄N₂O₃

Molecular Weight: 524.51 g/mol

Imlunestrant selectively binds to estrogen receptor alpha (ERα), inhibits estrogen receptor signaling, and promotes receptor degradation, thereby suppressing ER-dependent gene transcription and cancer cell proliferation. It is used for the treatment of ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer. This compound is an important targeted onc drug for research into endocrine-resistant breast cancer and estrogen receptor-targeted therapies.